Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: An evaluation of costs and effects

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 361-368

  Krieckaert, C L M ^a   Nair, S C ^b   Nurmohamed, M T ^a,c   Van Dongen, C J J ^a   Lems, W F ^c   Lafeber, F P J G ^b   Bijlsma, J W J ^b   Koffijberg, H ^b   Wolbink, G ^a,d   Welsing, P M J ^b  

^a Reade   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DAS28; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG COST; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ECONOMIC MODEL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIDDLE AGED; NONBIOLOGICAL MODEL; OUTCOME ASSESSMENT; PATIENT CARE; PERSONALIZED MEDICINE; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; TREATMENT DURATION; USUAL CARE; ARTHRITIS, RHEUMATOID; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; PROBABILITY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84921416740     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204101     Document Type: Article

References (31)

1. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
2. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
3. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
6. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
7. Pascual-Salcedo D, Plasencia C, Ramiro S. et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1445-52.
8. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
9. Miyasaka N. CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008;18:252-62.
10. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013;72:104-9.
11. Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken) 2010;62:1335-41.
12. Pavelka K, Jarosová K, Suchý D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-9.
13. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. adalimumab trough level in blood corresponding with clinical response. Ann Rheum Dis 2012;71(Suppl 3):359.
14. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18:349-58.
15. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
16. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?. Arthritis Rheum 2011;63:867-70.
17. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
18. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
19. Garcês S, Antunes M, Benito-Garcia E, et al. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2014;73:1138-43.
20. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013;11:654-66.
21. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
22. Van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
23. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;70:284-8.
24. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
25. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
26. Verstappen SMM, Verkleij H, Bijlsma JWJ, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004;63:817-24.
27. Verstappen S, Boonen A, Verkleij H, et al. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005;64:1754-60.
28. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Guideline for cost-of-illnessstudy; Methods and guideline-rates for economic evaluations in health care. Guideline for cost-of-illness study. Amstelveen, The Netherlands: College voorZorgverzekeringen, 2000.
29. Buxton MJ, Drummond MF, van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27.
30. Grutters JP, Kessels AG, Dirksen CD, et al. Willingness to accept versus willingness to pay in a discrete choice experiment. Value Health 2008;11:1110-19.
31. Whynes DK, Sach TH. WTP and WTA: do people think differently? Soc Sci Med 2007;65:946-57.